NF-kappaB in carcinoma therapy and prevention.

Authors:
Brown M, Cohen J, Arun P, Chen Z, Van Waes C
Associated Labs:
Dan Rockey Laboratory (National Institute of Health)
Expert Opin Ther Targets. 2008 Sep . 12(9):1109-22.
PMID: 18694378
BACKGROUND: NF-kappaB includes a family of signal-activated transcription factors that normally regulate responses to injury and infection but which are aberrantly activated in many carcinomas. OBJECTIVE: To review the activation and role of NF-kappaB in pathogenesis and as a target for treatment and prevention in carcinoma. METHODS: Evidence from experimental, epidemiological, preclinical studies and clinical trials cited in the literature are reviewed. RESULTS/CONCLUSION: Cumulative evidence implicates NF-kappaB in cell survival, inflammation, angiogenesis, spread and therapeutic resistance during tumor development, progression and metastasis of carcinomas. Non-specific natural and synthetic agents that inhibit NF-kappaB have demonstrated activity and safety in prevention or therapy. NF-kappaB-activating kinases and the proteasome are under investigation for targeted prevention and therapy of carcinoma.

Want to be recognized as an author of this publication?

Create your LabLife profile and tag yourself! You will also be able to tag other authors after you log into your account.

Create New Account

Login

What is LabLife?

LabLife is a collection of tools to help scientists organize, share and discover.

Learn more